Accepted Today, Read Tomorrow: How Articles in Press Are Reshaping Science Publishing

In the fast-moving world of scientific publishing, the gap between a manuscript’s formal acceptance and its appearance in a final, paginated journal issue has long been a source of frustration for researchers, journalists, and readers alike. A paper can be peer reviewed, approved by editors, and scientifically ready for weeks or even months before it appears in print. To close that gap, major publishers including Springer Nature, which operates journals such as BMC Pharmacology and Toxicology, have institutionalized a mechanism known as the Article in Press. Under this model, once a manuscript has been formally accepted after peer review, it is published online in an early-access version that carries a permanent Digital Object Identifier, or DOI, and can immediately be viewed, shared, and cited by the scientific community.

The technical foundation of the Article in Press system rests on the DOI, a persistent alphanumeric identifier assigned to a digital object that resolves through the DOI registry to a stable landing page. Because the DOI is assigned at the point of acceptance rather than at final publication, the early version of the paper acquires a citable identity from the very first day it appears online. Other researchers can reference the work in their own manuscripts, grant applications, and preprint discussions without waiting for the Version of Record. When the final, copy-edited and typeset version is later published, it replaces the Article in Press version while retaining exactly the same DOI, which means that every citation made in the interim continues to resolve correctly. This continuity of identifier is what makes early access compatible with the citation infrastructure that underpins modern scholarly communication.

Speed matters in science for reasons that go well beyond professional impatience. In fast-developing fields such as pharmacology and toxicology, where new drug candidates, emerging contaminants, and novel therapeutic targets are constantly under investigation, a delay of several months between acceptance and formal publication can mean the difference between a finding that shapes the next experiment and one that is scooped or rendered redundant. Early access allows laboratory groups to build on accepted results immediately, funding agencies to consider the newest evidence in their assessments, and clinicians in applied fields to see relevant toxicological data without waiting for a journal issue to close. For authors, the early appearance of a citable, DOI-bearing version also establishes priority in a landscape where preprint servers have made rapid disclosure the norm.

It is important to understand that an Article in Press is not an unreviewed or provisional scientific document. It is, by definition, an accepted manuscript, meaning it has already passed through the journal’s peer-review process and been approved for publication by the editors. What distinguishes it from the final Version of Record is the stage of production it has reached. The accepted manuscript may not yet reflect the full copy-editing, typesetting, and proofing work that transforms a submission into a polished journal article. Publishers make this status explicit by clearly labelling the document online, so that readers understand they are looking at an early version rather than the definitive record. All of the legal disclaimers that apply to the journal apply equally to the early version, preserving the same standards of accountability.

The production stage that follows acceptance is more than cosmetic, and publishers are candid about the possibility of change. According to the guidance accompanying journals that use this model, an Article in Press may be subject to further editing, because errors affecting the content can be discovered during the final production process. Errors identified in the early version are corrected during the author proofing stages, in which authors review the typeset article and flag discrepancies before the Version of Record is finalized. Corrections made at this stage are reflected in the final published version. This workflow acknowledges a practical reality of publishing: even after peer review, the mechanical and editorial processes of production can surface mistakes in figures, references, units, or wording that need to be fixed before the scientific record is considered complete.

For fully open access journals, the early-access service is offered on every accepted manuscript, making it a standard feature of the publication pipeline rather than an occasional privilege. This universality has significant implications for equity in science. Researchers at institutions with limited journal subscriptions, as well as practitioners and policymakers outside academia, can read accepted findings at the moment they become available, provided the journal is open access. In fields such as pharmacology and toxicology, where regulators, clinicians, and public health authorities all draw on the primary literature, the immediate availability of accepted manuscripts can accelerate the translation of research into practice. The open access model and the early access model are thus complementary: one removes the paywall, and the other removes the waiting period.

The rise of Articles in Press also intersects with the broader cultural shift toward preprints, the manuscripts that scientists post on community servers before peer review. Preprints maximize speed but carry no guarantee of quality control, while Articles in Press occupy a middle ground: they are slower than preprints but carry the imprimatur of formal acceptance and peer review. For many readers, this makes the Article in Press a uniquely trustworthy signal, combining the timeliness of early disclosure with the assurance that experts in the field have already scrutinized the methods and conclusions. Journals and publishers have increasingly emphasized this distinction in their communications, encouraging authors to share their accepted work widely while making clear that the definitive, proofed version will follow.

Authors preparing to publish under this model are also given practical guidance about visibility. Publishers advise researchers who wish to organize a press release around their Article in Press to contact their production editor as early as possible in the process. Early coordination matters because press outreach, institutional communications, and media embargoes all depend on knowing when the citable version will appear online. For high-profile findings, particularly those with clinical or public safety implications, the difference between a press release issued on the day of acceptance and one issued weeks later can determine how quickly the wider public and professional communities learn of the work. The guidance reflects an understanding that dissemination is now part of the publication workflow, not an afterthought.

Behind the scenes, the transition from Article in Press to Version of Record is managed so that the scholarly record remains coherent. The early version is hosted under the same DOI that will persist for the life of the article, and when the final version is published it simply replaces the early version at that identifier. Readers who bookmarked the article, cited it in reference managers, or linked to it from other papers will find the definitive version when they follow the same DOI. This design eliminates the broken links and duplicate records that plagued earlier eras of electronic publishing, when accepted manuscripts, preprints, and final versions sometimes circulated under different identifiers with no formal connection between them. The DOI, in effect, serves as the thread of continuity that ties the whole lifecycle of a paper together.

As scientific publishing continues to evolve, the Article in Press model illustrates a broader principle: the infrastructure of scholarly communication is being redesigned around immediacy without sacrificing rigor. Peer review still gates entry into the literature, production still polishes the final product, and the Version of Record still serves as the definitive citation of choice. But the long, silent interval between acceptance and publication, once an unavoidable feature of print-era workflows, has been compressed into a brief transitional phase that is transparent, labelled, and citable. For researchers in pharmacology, toxicology, and every other discipline served by this model, the message is straightforward: once your work is accepted, it is already part of the conversation, and the world can start reading it the same day.

Subject of Research: Early-access publishing of accepted peer-reviewed manuscripts as Articles in Press with persistent DOIs

Article Title: Articles in Press

Article References: Articles in Press. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Articles in Press, peer review, DOI, open access, scholarly publishing, Version of Record, Springer Nature, BMC Pharmacology and Toxicology, early access, scientific communication, manuscript acceptance, citation